Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$5.64 USD
-0.12 (-2.08%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.66 +0.02 (0.35%) 6:50 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Brokerage Reports
Anavex Life Sciences Corp. [AVXL]
Reports for Purchase
Showing records 41 - 60 ( 159 total )
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Rett Phase 2/3 Trial Enrollment Target Exceeded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Rett Syndrome Trial Exceeds Enrollment
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Shows Promise in Alzheimer''s Disease; Raising PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: ANAVEX2-73 Study Meets Its Primary and Key Secondary Endpoints
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: ANAVEX2-73 Study Meets Its Primary and Key Secondary Endpoints
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated Anavex Reports Topline Alzheimer?s Data Tomorrow. Investors Consider the Event Binary.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Orphan Drug Status in Fragile X Syndrome; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Date Presentation at CTAD: Anavex announces phase 2B/3 data of oral ANAVEX2-73 in early Alzheimer''s disease
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Patent Estate Broadened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
F3Q22 Financial Results; Lengthy Cash Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Anavex Reports 3rd Quarter Fiscal Results: $153M in Cash ? Multiple Catalysts
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Anavex announces the first entire clinical Alzheimer''s gene pathway data of ANAVEX 2-73
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Gene Pathway Data Reveals Blarcamesine Mechanistic Impact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Near-Term Clinical Data Catalysts; F2Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Parkinson''s Phase 2 Biomarker Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Clinical Programs Advancing Rapidly; F1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY: Anavex - Raising Price Target from $35.00 to $39.00
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J